[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR15C0010I1 - - Google Patents

Info

Publication number
FR15C0010I1
FR15C0010I1 FR15C0010C FR15C0010I1 FR 15C0010 I1 FR15C0010 I1 FR 15C0010I1 FR 15C0010 C FR15C0010 C FR 15C0010C FR 15C0010 I1 FR15C0010 I1 FR 15C0010I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0010(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0010I1 publication Critical patent/FR15C0010I1/fr
Application granted granted Critical
Publication of FR15C0010I2 publication Critical patent/FR15C0010I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR15C0010C 2003-06-12 2015-01-30 GLP-1 ANALOGUE HYBRID PROTEINS Active FR15C0010I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
PCT/US2004/015595 WO2005000892A2 (en) 2003-06-12 2004-06-10 Glp-1 analog fusion plroteins

Publications (2)

Publication Number Publication Date
FR15C0010I1 true FR15C0010I1 (en) 2015-03-13
FR15C0010I2 FR15C0010I2 (en) 2015-07-24

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0010C Active FR15C0010I2 (en) 2003-06-12 2015-01-30 GLP-1 ANALOGUE HYBRID PROTEINS

Country Status (29)

Country Link
US (2) US7452966B2 (en)
EP (2) EP2368909A1 (en)
JP (1) JP4629047B2 (en)
KR (1) KR100758755B1 (en)
CN (2) CN1802386B (en)
AR (1) AR044776A1 (en)
AT (1) ATE525395T1 (en)
AU (1) AU2004251145C1 (en)
BE (1) BE2015C007I2 (en)
BR (1) BRPI0411132B8 (en)
CA (1) CA2528591C (en)
CY (2) CY1111991T1 (en)
DK (1) DK1641823T3 (en)
EA (1) EA008831B1 (en)
ES (1) ES2371072T3 (en)
FR (1) FR15C0010I2 (en)
HK (1) HK1149566A1 (en)
HR (1) HRP20110714T1 (en)
HU (1) HUS1500024I1 (en)
IL (1) IL171926A (en)
LT (1) LTC1641823I2 (en)
MX (1) MXPA05013565A (en)
NZ (1) NZ543292A (en)
PL (1) PL1641823T3 (en)
PT (1) PT1641823E (en)
SI (1) SI1641823T1 (en)
TW (1) TW200507870A (en)
UA (1) UA87458C2 (en)
WO (1) WO2005000892A2 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
CN1802386B (en) * 2003-06-12 2010-12-15 伊莱利利公司 GLP-1 analog fusion proteins
KR101184391B1 (en) 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
MX2007007565A (en) * 2004-12-22 2007-07-24 Lilly Co Eli Glp-1 analog fusion protein formulations.
DK1881850T3 (en) * 2005-05-13 2011-01-03 Lilly Co Eli GLP-1-PEGylated Compounds
CN101273134B (en) * 2005-07-27 2012-01-04 王庆华 Glp/1/exendin 4 igg fc fusion constructs for treatment of diabetes and method
CN101277722A (en) 2005-08-06 2008-10-01 王庆华 Composition and method for prevention and treatment of type I diabetes
DE602005017628D1 (en) * 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusion polypeptides of glp-1 (glucagon-like peptide-1) with increased peptidase resistance
KR20080071134A (en) * 2005-10-24 2008-08-01 센토코 인코포레이티드 Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP3095456A1 (en) * 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
ES2572952T3 (en) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Glucagon analogs showing physiological solubility and stability
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
WO2008028117A2 (en) * 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CN103230598A (en) * 2006-09-06 2013-08-07 费斯生物制药公司 Fusion peptide therapeutic compositions
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR101542752B1 (en) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 Modified coagulation factors with prolonged in vivo half-life
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8669228B2 (en) * 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
JP2008169195A (en) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
EP2526962B1 (en) 2007-02-12 2019-08-14 CSL Behring GmbH Therapeutic application of Kazal-type serine protease inhibitors
CN101790538B (en) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 Ucagon/glp-1 receptor co-agonists
JP5431171B2 (en) * 2007-03-15 2014-03-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of autoimmune disorders
KR20100049032A (en) * 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 Glp-1 peptide having sugar chain attached thereto
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (en) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
MX2010004298A (en) * 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compounds exhibiting glucagon antagonist and glp-1 agonist activity.
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
AU2009260301B2 (en) * 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL2300035T3 (en) * 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
ES2579502T3 (en) 2008-06-17 2016-08-11 Indiana University Research And Technology Corporation Glucagon / GLP-1 receptor coagonists
DK2291523T3 (en) 2008-06-24 2015-03-23 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
JP5878757B2 (en) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド FGF21 variants and uses thereof
CN102325539A (en) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP2012525847A (en) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド FGF21 variants and uses thereof
JP5823954B2 (en) 2009-05-05 2015-11-25 アムジエン・インコーポレーテツド FGF21 variants and uses thereof
RU2012101274A (en) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon Compounds Active Against the GIP Receptor
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
CN101993485B (en) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
WO2011043530A1 (en) * 2009-10-09 2011-04-14 (주)알테오젠 Glp-1 analog fusions, and composition for preventing or treating diabetes containing the fusions as an active ingredient
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
BR112012018585A2 (en) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp antagonist-gon agonist glucagon compositions and compositions for the treatment of metabolic disorders and obesity
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CA2793715A1 (en) 2010-04-30 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
KR20130111923A (en) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
JP6121323B2 (en) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Peptides of the glucagon superfamily exhibiting nuclear hormone receptor activity
CN101891823B (en) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
JP2013540102A (en) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Peptide prodrugs of the glucagon superfamily modified via amide bonds
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
DK2683397T3 (en) 2011-03-09 2017-09-18 Csl Behring Gmbh FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
MX354359B (en) 2011-03-29 2018-02-28 Roche Glycart Ag Antibody fc variants.
HUE035776T2 (en) 2011-06-22 2018-05-28 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2734552B1 (en) 2011-07-22 2024-11-13 CSL Behring GmbH Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
BR112014007124A2 (en) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamily of gluxagon peptides that exhibit glucocorticoid receptor activity
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
PL2814502T3 (en) 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
LT2872534T (en) 2012-07-13 2018-10-25 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
ES2684549T3 (en) * 2012-09-12 2018-10-03 Genzyme Corporation Polypeptides containing Fc with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
KR102385392B1 (en) 2012-11-27 2022-04-11 바이오마린 파머수티컬 인크. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
DK2964255T3 (en) 2013-03-08 2021-02-08 Csl Behring Gmbh Treatment and prevention of distant ischemia-reperfusion injury (IRI)
CN111875705B (en) 2013-03-11 2024-04-02 建新公司 Highly glycosylated binding polypeptides
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
JP2017501968A (en) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Combination therapy using factor XII inhibitor and C1-inhibitor
CN103408669B (en) 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 GLP-1 analog fusion, and its production and use
CN104592381A (en) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 Preparation method of liraglutide intermediate polypeptide
JP6712230B2 (en) 2014-03-11 2020-06-17 ノバルティス アーゲー Methods for treating metabolic disorders associated with lipodystrophy and defective insulin production or defective insulin signaling
CN106471010A (en) 2014-03-19 2017-03-01 建新公司 The locus specificity of targeting module is Glyco-engineered
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
JP6676551B2 (en) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Modified von Willebrand factor
CA2954847A1 (en) 2014-07-21 2016-01-28 Jeffrey Greve Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
NZ728175A (en) 2014-08-11 2023-03-31 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN104293834B (en) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP 1 or its analog and antibody Fc fragment fusion protein preparation method
PL3236991T3 (en) 2014-12-23 2019-12-31 Novo Nordisk A/S Fgf21 derivatives and uses thereof
KR101825048B1 (en) 2014-12-31 2018-02-05 주식회사 제넥신 Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof
BR112017021696A2 (en) 2015-04-10 2018-07-10 Amgen Inc interleukin-2 muteins for regulatory t-cell expansion
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
BR112017024714A2 (en) 2015-05-22 2018-09-11 Csl Behring Recombinant Facility Ag methods for preparing modified von willebrand factor
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
KR102670157B1 (en) 2015-10-28 2024-05-29 주식회사유한양행 Dual function proteins and pharmaceutical composition comprising the same
KR102668200B1 (en) 2015-10-28 2024-05-23 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
MA44154A (en) 2015-12-23 2018-10-31 Amgen Inc METHOD OF TREATMENT OR AMELIORATION OF METABOLIC DISORDERS USING GASTRIC PEPTIDE INHIBITOR (GIPR) RECEPTOR BIND PROTEIN (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
US10808023B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated von Willebrand factor
JP6851381B6 (en) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Mutant cleavage type von Will brand factor
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109071629A (en) 2016-04-06 2018-12-21 杰特有限公司 The method for treating atherosclerosis
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC Antibody conjugates and methods of making and using the same
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN107759697B (en) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 Method for producing fusion protein
WO2018032638A1 (en) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 Linker peptide for constructing fusion protein
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
CN110167957A (en) 2016-11-08 2019-08-23 德里尼亚公司 For treating the IL-2 variant of autoimmune disease
MX2019005380A (en) 2016-11-10 2019-08-12 Yuhan Corp Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins.
TW201828975A (en) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 Truncated von Willebrand factor polypeptides for treating hemophilia
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
KR102664780B1 (en) 2017-04-21 2024-05-13 주식회사유한양행 Method for producing dual function proteins and its derivatives
RS64666B1 (en) 2017-06-01 2023-11-30 Lilly Co Eli Dulaglutide for the treatment of chronic kidney disease
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
MX2020002977A (en) 2017-09-22 2020-11-06 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof.
BR112020007817A2 (en) 2017-11-21 2020-10-06 Eli Lilly And Company method of use and compositions containing dulaglutide
CN109929806B (en) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 Stem cell expressing GLP1 and FGF21 and application thereof
US11491235B2 (en) 2017-12-22 2022-11-08 Kb Biomed Inc. Oral gene carrier and use thereof
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019154189A1 (en) 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
AU2019308089A1 (en) 2018-07-19 2021-01-21 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
KR20200135618A (en) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease comprising a polypeptide
CN110878127B (en) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 Long-acting recombinant GLP1-Fc-CD47 protein and preparation and application thereof
CN111234000B (en) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 Ai Saina peptide analogues
CN111269312B (en) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 Heterologous fusion protein
CN109836486B (en) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 Fibroblast growth factor 21 variants, fusion proteins thereof, and uses thereof
EP3935075A4 (en) * 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CA3131912A1 (en) 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
US20220143187A1 (en) * 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
AU2020277640A1 (en) 2019-05-17 2022-01-20 Csl Behring Ag Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
CN114555792A (en) 2019-10-15 2022-05-27 伊莱利利公司 Recombinant engineered, lipase/esterase deficient mammalian cell lines
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN113728013B (en) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Conjugates of fusion proteins of GLP-1 and FGF21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
MX2023002293A (en) 2020-08-24 2023-05-19 Univ Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases.
CN114106194B (en) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 Fusion protein for treating diabetes and/or obesity
US20240000908A1 (en) 2020-11-20 2024-01-04 Csl Behring Gmbh Method for Treating Antibody-Mediated Rejection
CN114685644A (en) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 Human GLP-1 polypeptide variant and application thereof
EP4284407A1 (en) 2021-02-01 2023-12-06 CSL Behring AG Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
WO2023280133A1 (en) 2021-07-06 2023-01-12 苏州康宁杰瑞生物科技有限公司 Fusion protein and application thereof
TW202409070A (en) 2022-05-18 2024-03-01 美商普羅托莫科技公司 Aromatic boron-containing compounds and related insulin analogs
CN114774496B (en) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 Method for preparing GLP-1 analogue through high-density fermentation
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
TW202421654A (en) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 Methods for treating obesity
WO2024132147A1 (en) 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists
US20240318221A1 (en) 2023-03-23 2024-09-26 Eli Lilly And Company Methods of producing fc-containing proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0394538B1 (en) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh A yeast cell of the genus schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
AU669960B2 (en) 1992-11-13 1996-06-27 Immunex Corporation Novel cytokine designated elk ligand
CN1117155C (en) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 Novel compounds
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (en) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
DE60006100T2 (en) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal LONG-LASTING INSULINOTROPE PEPTIDES
DK1695983T3 (en) 2000-06-16 2009-05-18 Lilly Co Eli Glucagon-like peptide-1 analogues
CN1483041A (en) * 2000-12-07 2004-03-17 GLP-1 fusion protein
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
CN1802386B (en) * 2003-06-12 2010-12-15 伊莱利利公司 GLP-1 analog fusion proteins

Also Published As

Publication number Publication date
CN101974090A (en) 2011-02-16
ATE525395T1 (en) 2011-10-15
UA87458C2 (en) 2009-07-27
HUS1500024I1 (en) 2017-04-28
DK1641823T3 (en) 2011-12-12
EP2368909A1 (en) 2011-09-28
KR100758755B1 (en) 2007-09-14
KR20060022262A (en) 2006-03-09
EP1641823A2 (en) 2006-04-05
JP4629047B2 (en) 2011-02-09
CY1111991T1 (en) 2015-11-04
CN101974090B (en) 2015-06-17
LTC1641823I2 (en) 2016-12-12
CY2015002I1 (en) 2015-11-04
NZ543292A (en) 2008-04-30
US8273854B2 (en) 2012-09-25
TW200507870A (en) 2005-03-01
HRP20110714T1 (en) 2011-11-30
CA2528591A1 (en) 2005-01-06
CN1802386B (en) 2010-12-15
WO2005000892A3 (en) 2005-03-03
IL171926A (en) 2010-12-30
EA008831B1 (en) 2007-08-31
US7452966B2 (en) 2008-11-18
EA200600015A1 (en) 2006-06-30
SI1641823T1 (en) 2011-12-30
PT1641823E (en) 2011-11-08
CY2015002I2 (en) 2017-04-05
AU2004251145B2 (en) 2010-09-09
US20090074769A1 (en) 2009-03-19
FR15C0010I2 (en) 2015-07-24
US20070036806A1 (en) 2007-02-15
BRPI0411132A (en) 2006-07-18
AU2004251145C1 (en) 2011-04-14
EP1641823B1 (en) 2011-09-21
BRPI0411132B8 (en) 2021-05-25
AU2004251145A1 (en) 2005-01-06
JP2007536902A (en) 2007-12-20
HK1149566A1 (en) 2011-10-07
PL1641823T3 (en) 2012-02-29
IL171926A0 (en) 2006-04-10
MXPA05013565A (en) 2006-03-09
WO2005000892A2 (en) 2005-01-06
CA2528591C (en) 2013-01-08
BRPI0411132B1 (en) 2016-12-13
ES2371072T3 (en) 2011-12-27
CN1802386A (en) 2006-07-12
BE2015C007I2 (en) 2023-08-09
AR044776A1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
BE2015C007I2 (en)
BE2013C069I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
JP2004012123A5 (en)
BE2013C034I2 (en)
JP2004127940A5 (en)
JP2004215137A5 (en)
JP2004066812A5 (en)
AU2002348177A1 (en)
AU2002311957A1 (en)
AU2002359010A1 (en)
AU2002355123A1 (en)
AU2002362930A1 (en)
AU2002353888A1 (en)
AU2001256599A1 (en)
JP2004220818A5 (en)
AU2002316235A1 (en)
AU2002351829A1 (en)
JP2004087469A5 (en)
AU2002321535A1 (en)
AU2002242943A1 (en)
AU2002345911A1 (en)
AU2002245368A1 (en)